TG Therapeutics entered a licensing agreement with Ligand Pharmaceuticals for exclusive global rights to develop and commercialize Ligand’s IRAK4 inhibitor research program currently in preclinical development.   IRAK4 is a signaling kinase associated with mutations of MYD88, which can be found in most patients with Waldenstrom’s Macroglobulinemia, a rare B-cell cancer, and certain patients with Non-Hodgkin’s Lymphoma and chronic lymphocytic leukemia. Additionally, IRAK4 is a k...